Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol
Annals of Pharmacotherapy · 2023-03 · 57 (3) · 317-324
DOI: 10.1177/10600280221105169 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, online erschienen am 30.06.2022. Verfasst von Essie Samuel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, School of Pharmacy, Philadelphia College of Osteopathic Medicine, Suwanee, GA, USA. Hauptthemen laut MEDLINE: Atherosclerosis, Anticholesteremic Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Objective
To review the current pharmacology, pharmacokinetics/pharmacodynamics, safety, and efficacy of inclisiran in lowering lipid levels. Data Sources: A PubMed (from December 1, 2014 to April 15, 2022) and ClinicalTrials.gov search was conducted using ALN-PCSsc, ALN-60212, PCSK9si KJX-839, and inclisiran. Additional articles were identified by hand from references. Study Selection and Data Extraction: We included English-language articles evaluating inclisiran pharmacology, efficacy, or safety in humans for lowering low-density lipoprotein cholesterol (LDL-C). Data Synthesis: Inclisiran is a novel small interfering RNA-based therapy administered as a twice-yearly subcutaneous injection. By binding to the messenger RNA (mRNA) precursor of proprotein convertase subtilisin/kexin type 9 (PCSK9), inclisiran inhibits expression of the PCSK9 gene, resulting in increased recycling and expression of LDL receptors and decreased levels of LDL-C. Like PCSK9 inhibitors, inclisiran was associated with a comparable extent of LDL-C reduction in several phase II/III trials. Compared with placebo, inclisiran was found to have similar adverse events except for injection-site reaction. Relevance to Patient Care and Clinical Practice: Currently, inclisiran lacks data on clinical outcome improvement or long-term safety. However, it may play a role in patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalent if optimal LDL-C cannot be achieved by statins and PCSK9 inhibitors cannot be tolerated. The drug may be used for heterozygous familial hypercholesterolemia.
Conclusion
Inclisiran is an effective and safe medication for lowering LDL-C levels. Additional data regarding efficacy on cardiovascular outcomes and long-term safety profile with inclisiran are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, School of Pharmacy, Philadelphia College of Osteopathic Medicine, Suwanee, GA, USA.
- Heart Failure Treatment and Recovery Center, Georgia Heart Institute, Gainesville, GA, USA.
- Department of Clinical Sciences, College of Pharmacy, California Health Sciences University, Clovis, CA, USA.
- SynerGrx, Chamblee, GA, USA.
ORCID-Profile: Drew W Cates
Zitieren
APA
Samuel, E., Watford, M., Egolum, U. O., Ombengi, D. N., Ling, H., & Cates, D. W. (2023). Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol. Annals of Pharmacotherapy, 57(3), 317-324. https://doi.org/10.1177/10600280221105169
Vancouver
Samuel E, Watford M, Egolum UO, Ombengi DN, Ling H, Cates DW. Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol. Annals of Pharmacotherapy. 2023;57(3):317-324. doi:10.1177/10600280221105169
BibTeX
@article{Samuel2023,
author = {Samuel, Essie and Watford, Maya and Egolum, Ugochukwu O and Ombengi, David N and Ling, Hua and Cates, Drew W},
title = {Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol},
journal = {Annals of Pharmacotherapy},
year = {2023},
volume = {57},
number = {3},
pages = {317--324},
doi = {10.1177/10600280221105169}
}
EUVIMED